Cyclosporin and plasmapheresis in treatment of progressive systemic lupus erythematosus (pSLE)

Transfusion Science

Volumn 18, Issue 1, 1997, Pages 91-97

  Schiel, Ralf ^a,b   Bambauer, Rolf ^b   Latza, Reinhard ^b   Klinkmann, Jens ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIBODY TITER; ARTICLE; BLEEDING; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; INFECTION; MALE; PLASMAPHERESIS; PROGNOSIS; QUALITY OF LIFE; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; VOMITING;

ADOLESCENT; ADULT; CYCLOSPORINE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLASMAPHERESIS; TREATMENT OUTCOME;

EID: 0346046270     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(96)00082-3     Document Type: Article

References (43)

1. Tan EM, Foreword. In: Lahita RG, (ed.): Systemic Lupus Erythematosus, Churchill Livingstone, New York, 1992, pp. XV-I
2. Boumpas DT, Austin HA, Fessier BJ, Balow IE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatrie, cardiovascular, pulmonary, and hematologic disease. Ann Int Med 1995; 122:940-950.
3. Gladman DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5 (5):587-595.
4. Hochberg MC, Petri M: Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5 (5):575-586.
5. Fessler BJ, Boumpas DT: Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995; 21 (1):81-98.
6. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL: Systemic lupus erythematosus-survival patterns: experience with 609 patients. J Am Med Assoc 1981, 245:934-938.
7. Austin HA, Klippel JH, Balow JE, et al: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
8. McCune WI, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe lupus erythematosus. N Engl J Med 1988; 318:1423-1431.
9. Lehmann TJ, Sherry DD, Wagner-Weiner L, et al.: Intermittent intravenous cyclosphosphamide therapy for lupus nephritis. J Pediatr 1989; 114:1055-1060.
10. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34:945-950.
11. Wonigeit K: Gegenwärtiger Stand der Immunsuppression bei der Organtrans-plantation. Chirurg 1988; 59:447-453.
12. Wiesinger D, Borel JF: Studies on the mechanism of action of cyclosporin A. Immunobiol 1979; 156:454-463.
13. Wagner H, Hardt C, Heeg K: Wirkungs-mechnismus des Cyclosporin A. Internist 1985; 26:530-533.
14. Hof H: Infektionsrisiko bei der Behandlung mit Cyclosporin A. Dtsch Med Wochenschr 1986; 111:1770-1775.
15. Sandoz AG, Sandimmun® (Ciclosporin). Sandoz, AG, Basel, Switzerland, 1990.
16. Schur PH, Sandsonb J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Eng J Med 1968; 278:533-538.
17. Ellis CN, Gorsulowsky DC, Hamilton TA, et al: Cyclosporin improves psoriasis in a double-blind study. J Amer Med Ass 1986; 256:3110-3116.
18. Joost TH van, Bos JD, Heule F, Meinardi MMHM: Low dose cyclosporin A in severe psoriasis. A double-blind study. Brit J Dermatol 1988; 118:183-190.
19. Masuda K, Urayama A, Kogure M, Nakajima A, Nakae K, Inaba G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989; 1:1093-1096.
20. Rudge P, Koetsier JC, Mertin J, et al.: Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiat 1989; 52:559-565.
21. Frey FJ: Cyclosporin bei Autoimmunerkrankungen. Schweiz Med Wochenschr 1990; 120:772-786.
22. Bambauer R, Jutzler GMA, Pees H, et al.: Cyclosporin (CyA) and therapeutic plasma exchange in steroid-resistant SLE, in Schindler R, (ed.), Cyclosporin in Autoimmune Diseases. Springer, Berlin, Heidelerg, New York, Tokyo, 1985, pp. 346-355.
23. Bambauer R, Jutzler GA, Pees H, et al.: Therapeutic plasma exchange and cyclosporin A in steroid-resistant lupus erythematosusi, in Bambauer PS, Malchesky PS, Falkenhagen D, (eds), Therapeutic Plasma Exchange and Selective Plasma Separation. Schattauer, Stuttgart, New York, 1987, pp. 49-75.
24. Bambauer R, Reinelt B, Pees H, Schwarze G, Keller HE, Berberich R: Therapeutic plasma exchange and cyclosporin A in severe systemic lupus erythematosus. Transfus Sci 1989; 10:147-154.
25. Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ: Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9 (1):57-60.
26. Tokuda M, Kurata N, Mizoguchi A, et al.: Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37:837-839.
27. Schiel R, Bambauer R: Cyclosporin bei der Behandlung von Autoimmunerkrankungen. Med Welt 1995; 46:226-229.
28. Lewis EJ: Plasmapheresis therapy is ineffective in SLE Lupus nephritis collaborative study group. J Clin Apheresis 1992; 7 (3):153.
29. Lombardo R, Cepparrone F, Di Pietro G, Franco C, Graziani G, Avanzi G: Plasma exchange in systemic lupus erythematosus. Experience in thirty-seven patients. Int J Artif Organs 1993; 16 (5):177-179.
30. Suzuki K, Matsuki Y, Hidaka T et al.: Double filtration plasmapheresis in a patient with autoimmune hepatitis-systemic lupus erythematosus overlap. Intern Med 1993; 32 (9):725-729.
31. Euler HH, Guillevib L: Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interin report of the Lupus Plasmapheresis Study Group. Ann Med Interne Paris 1994; 145 (5):296-302.
32. Bambauer R, Jutzler GA, Mauch H, Keller HE, Zaun H: Ein vereinfachtes Plasmapherese-Behandlungsverfahren. Technik und erste klinische Ergebnisse. Nieren-und Hochdruckkrankheiten 1981; 10:126-134.
33. Bambauer R, Inniger R, Pirrun KJ, Schiel R, Dahlem R: Complications and side-effects associated with large-bore catheters in the subclavian and internal jugular veins. Artif Organs 1994; 18 (4):318-321.
34. Bambauer R, Schiel R, Mestres P, Sioshansi P: Scanning electron microscopic investigations of surface treated largebore catheters used for extracorporeal detoxification methods. Int J Artif Organs 1995; 18:326-331.
35. Bambauer R, Jutzler GA, Keller HE, Becker HG: Single needle plasmapheresis, in Ringoir S, Vanholder R, Ironorich P, (eds), First International Symposium on Single-needle Dialysis. ISAO Press, Cleveland, 1984, pp. 223-243.
36. Fahr A, Hiestand P, Ryffel B: Studies on the biologic activities of SandimmunR metabolites in humans and in animal models: review and original experiments. Transplant Proc 1990; 22:1116-1124.
37. Blank M, BenBassat M, Shoenfeld Y: The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum 1992; 35:1350-1355.
38. Graffenried B von, Krupp P: Nebenwirkungen von Ciclosporin nach Nieren-transplantationen und bei Patienten mit Autoimmunerkrankungen. Internist 1985; 26:342-348.
39. Bambauer R, Weber U, Berberich R: Nephrotoxitzität von Cyclosporin A in der Behandlung des systemischen Lupus erythematodes. Nierenund Hochdruckkrankh 1990; 19:452-454.
40. Fernandez-Sola J, Campistol J, Casademont J, Grau JM, Urbano-Marquez A: Reversible cyclosporin myopathy. Lancet 1990; 1:362-363.
41. Whith DJG: Cyclosporin A clinical pharmacology and therapeutic potential. Drugs 1982; 24:322-334.
42. Wonigkeit K: Pharmakokinetik von Ciclosporin A und Bedeutung der Blut-spiegelmessung für die Therapie. Internist 1985; 26:534-542.
43. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM: A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326 (21):1373-1379.